Christopher Pieczonka

6PUBLICATIONS
30CO-AUTHORS
Radiation therapyPredictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 02, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

Evan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka

|Sep 22, 2025
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.

Neal D Shore, Christopher M Pieczonka, Sean Heron

|Apr 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.

Emmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka

|Apr 13, 2022
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.

Mark C Markowski, Ronald Tutrone, Christopher Pieczonka

|Oct 08, 2020
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Arif Hussain, Abhishek Tripathi, Christopher Pieczonka

|Aug 12, 2020
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.

Neal D Shore, Charles G Drake, Daniel W Lin

Pageof 1

Frequent Collaborators

3 joint publications

Neal D Shore

2 joint publications

Lawrence I Karsh

1 joint publications

Emmanuel S Antonarakis

1 joint publications

Sumit K Subudhi